| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_626863861e6d4daa260371937ae326a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06c87200cf96acdabeae38cd1101927d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_863785e4f0e730175e0f6a095ac08a27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2453aa7645dafce18e9d814dd8f9f3f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78610af38c38109857d2f4127e251e33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a1c7168fe3333762d0b302cf0b7797e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-445 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-06 |
| filingDate |
2000-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a6acdd1b6fec56b8fc7ff68666aae09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c16fd372455180022e0529c6af0b8a8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0354508a2da0ecd39c42da97be01f712 |
| publicationDate |
2001-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0134188-A1 |
| titleOfInvention |
Malaria vaccine |
| abstract |
We utilized the silkworm (Bombyx mori)/baculovirus system to produce recombinant Major Merozoite Surface Protein (1) (MSP142) because of the low cost and potential high yield of this expression system. The MSP142 (3D7 sequence) was cloned into the baculovirus, BmNPV with the melittin signal sequence. The recombinant virus, BmNPV-Sp42 was used to infect silkworms for the expression of MSP142 (Sp42). One recombinant clone expressed high level of Sp42 with an estimated 0.5 mg of antigen produced within a single worm. The Sp42 was recognized by monoclonal and polyclonal antibodies specific for parasite MSP1 in direct binding and competitive binding ELISAs, suggesting that Sp42 possesses antigenic determinants similar to parasite MSP142. Immunogenicity studies were performed in rabbits. Sp42 induced high titers of antibodies crossreactive with MSP1. Specificity analyses showed that anti-Sp42 antibodies reacted primarily against conserved determinants on MSP1-19. Our results showed that the silkworm expression system can produce recombinant MSP142 that are antigenically and immunogenically comparable to other recombinant MSP1 antigens expressed in other eukaryotic systems. The low cost at high level of protein expression makes it an attractive alternative for the development of a human malaria vaccine. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7256281-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007006052-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8211447-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1497307-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7563883-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102533677-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102533677-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1497307-A4 |
| priorityDate |
1999-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |